5.77 USD
-0.02 (-0.35%)
5.76 USD
-0.01 (-0.17%)
Overall MNKD gets a fundamental rating of 5 out of 10. We evaluated MNKD against 530 industry peers in the Biotechnology industry. MNKD has an average financial health and profitability rating. MNKD is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
MNKD had positive earnings in the past year.
In the past year MNKD had a positive cash flow from operations.
In the past 5 years MNKD reported 4 times negative net income.
In multiple years MNKD reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of MNKD (5.81%) is better than 92.08% of its industry peers.
Looking at the Return On Invested Capital, with a value of 18.48%, MNKD belongs to the top of the industry, outperforming 97.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROIC | 18.48% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 9.16%, MNKD belongs to the best of the industry, outperforming 90.75% of the companies in the same industry.
Looking at the Operating Margin, with a value of 27.48%, MNKD belongs to the top of the industry, outperforming 96.23% of the companies in the same industry.
Looking at the Gross Margin, with a value of 78.49%, MNKD belongs to the top of the industry, outperforming 84.72% of the companies in the same industry.
In the last couple of years the Gross Margin of MNKD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MNKD is creating value.
Compared to 1 year ago, MNKD has more shares outstanding
Compared to 5 years ago, MNKD has more shares outstanding
Compared to 1 year ago, MNKD has an improved debt to assets ratio.
2.2 Solvency
MNKD has an Altman-Z score of -5.21. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.21, MNKD is doing worse than 63.02% of the companies in the same industry.
The Debt to FCF ratio of MNKD is 8.39, which is on the high side as it means it would take MNKD, 8.39 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MNKD (8.39) is better than 91.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Altman-Z | -5.21 |
ROIC/WACC2.18
WACC8.46%
2.3 Liquidity
A Current Ratio of 3.29 indicates that MNKD has no problem at all paying its short term obligations.
MNKD has a worse Current ratio (3.29) than 60.94% of its industry peers.
MNKD has a Quick Ratio of 3.04. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
MNKD has a worse Quick ratio (3.04) than 61.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 174.00% over the past year.
The Revenue has grown by 17.44% in the past year. This is quite good.
The Revenue has been growing by 35.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
3.2 Future
MNKD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.41% yearly.
Based on estimates for the next years, MNKD will show a quite strong growth in Revenue. The Revenue will grow by 18.25% on average per year.
EPS Next Y-0.55%
EPS Next 2Y17.07%
EPS Next 3Y35.31%
EPS Next 5Y52.41%
Revenue Next Year20.91%
Revenue Next 2Y21.56%
Revenue Next 3Y18.34%
Revenue Next 5Y18.25%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 41.21, the valuation of MNKD can be described as expensive.
Based on the Price/Earnings ratio, MNKD is valued cheaply inside the industry as 91.13% of the companies are valued more expensively.
MNKD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.84.
A Price/Forward Earnings ratio of 52.62 indicates a quite expensive valuation of MNKD.
MNKD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MNKD is cheaper than 90.57% of the companies in the same industry.
MNKD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.21 | ||
| Fwd PE | 52.62 |
4.2 Price Multiples
MNKD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MNKD is cheaper than 94.34% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 93.21% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.84 | ||
| EV/EBITDA | 18.1 |
4.3 Compensation for Growth
A more expensive valuation may be justified as MNKD's earnings are expected to grow with 35.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.07%
EPS Next 3Y35.31%
5. Dividend
5.1 Amount
MNKD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.77
-0.02 (-0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners57.05%
Inst Owner Change2.16%
Ins Owners1.6%
Ins Owner Change-0.5%
Market Cap1.77B
Revenue(TTM)313.79M
Net Income(TTM)28.75M
Analysts85.33
Price Target9.24 (60.14%)
Short Float %7.33%
Short Ratio5.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)53.26%
Min EPS beat(2)-100%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)19.34%
Min EPS beat(4)-100%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-31.68%
EPS beat(12)5
Avg EPS beat(12)-2.87%
EPS beat(16)6
Avg EPS beat(16)-4.99%
Revenue beat(2)1
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-4.55%
Max Revenue beat(2)0.33%
Revenue beat(4)3
Avg Revenue beat(4)-0.74%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)0.9%
Revenue beat(8)6
Avg Revenue beat(8)1.65%
Revenue beat(12)8
Avg Revenue beat(12)2.45%
Revenue beat(16)11
Avg Revenue beat(16)3.58%
PT rev (1m)-0.08%
PT rev (3m)-14.34%
EPS NQ rev (1m)31.21%
EPS NQ rev (3m)-42.94%
EPS NY rev (1m)-16%
EPS NY rev (3m)-26.21%
Revenue NQ rev (1m)-0.7%
Revenue NQ rev (3m)10.88%
Revenue NY rev (1m)5.89%
Revenue NY rev (3m)4.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.21 | ||
| Fwd PE | 52.62 | ||
| P/S | 5.65 | ||
| P/FCF | 40.84 | ||
| P/OCF | 36.26 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 18.1 |
EPS(TTM)0.14
EY2.43%
EPS(NY)0.11
Fwd EY1.9%
FCF(TTM)0.14
FCFY2.45%
OCF(TTM)0.16
OCFY2.76%
SpS1.02
BVpS-0.15
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROCE | 22.37% | ||
| ROIC | 18.48% | ||
| ROICexc | 48.2% | ||
| ROICexgc | 50.4% | ||
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% | ||
| FCFM | 13.83% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Debt/EBITDA | 3.59 | ||
| Cap/Depr | 64.99% | ||
| Cap/Sales | 1.74% | ||
| Interest Coverage | 9.12 | ||
| Cash Conversion | 51.63% | ||
| Profit Quality | 150.89% | ||
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 | ||
| Altman-Z | -5.21 |
F-Score8
WACC8.46%
ROIC/WACC2.18
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
EPS Next Y-0.55%
EPS Next 2Y17.07%
EPS Next 3Y35.31%
EPS Next 5Y52.41%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
Revenue Next Year20.91%
Revenue Next 2Y21.56%
Revenue Next 3Y18.34%
Revenue Next 5Y18.25%
EBIT growth 1Y48.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y237.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y386.62%
OCF growth 3YN/A
OCF growth 5YN/A
MANNKIND CORP / MNKD FAQ
What is the fundamental rating for MNKD stock?
ChartMill assigns a fundamental rating of 5 / 10 to MNKD.
What is the valuation status for MNKD stock?
ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.
Can you provide the profitability details for MANNKIND CORP?
MANNKIND CORP (MNKD) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for MNKD stock?
The Earnings per Share (EPS) of MANNKIND CORP (MNKD) is expected to decline by -0.55% in the next year.